Statistics from Altmetric.com
Q In infants and young children with acute viral bronchiolitis, do systemic corticosteroids shorten hospital length of stay (LOS) or improve respiratory distress more than placebo or no corticosteroid treatment?
Clinical impact ratings GP/FP/Emergency Medicine ★★★★★★☆ GP/FP/Primary Care ★★★★★☆☆ Emergency Medicine (specialist) ★★★★★☆☆ Paediatrics (Specialist) ★★★★★★☆ Respirology ★★★★★☆☆
Cochrane Central Register of Controlled Trials (issue 3, 2003), Medline (1966 to September 2003), EMBASE/Excerpta Medica (January 1990 to September 2003), Current Contents (1998–2000), and SCISEARCH; reference lists of general paediatric, infectious diseases, and respirology textbooks; reference lists of retrieved studies and recent review articles; meeting abstracts; authors of published abstracts; and experts in the field.
Study selection and assessment:
randomised controlled trials (RCTs) in any language that evaluated systemic corticosteroids in infants and young children ⩽24 months of age with acute viral bronchiolitis. Study quality was assessed using the Jadad scale.
hospital LOS and clinical severity scores (degree of respiratory distress over time). Hospital admissions were assessed in patients recruited from the emergency department (ED).
13 RCTs met the selection criteria (n = 1198, age range 0–30 mo). 10 trials were set in inpatient paediatric hospital wards; 3 trials recruited patients from the ED and outcomes were measured in hospital or at home. Hospital LOS data were pooled in 7 RCTs of inpatients; groups did not differ for LOS (table). In 3 RCTs where recruitment and the start of intervention occurred in the ED, groups did not differ for hospital admission rates (table). Clinical score data pooled in 8 RCTs showed no difference between groups in day 3 clinical score (table).
In infants and young children with acute viral bronchiolitis, systemic corticosteroids do not shorten hospital length of stay or improve respiratory distress more than placebo or no corticosteroid treatment.
Viral bronchiolitis is a common lower respiratory tract infection in infants and a frequent cause of hospital admission. The systematic review by Patel et al adds to a list of previous Cochrane reviews that all failed to show a significant effect on clinically relevant outcomes (eg, LOS or requirement for mechanical ventilation) for any of the treatments that are currently widely used (ie, inhaled bronchodilators, adrenaline or corticosteroids, immunoglobulins, and ribavirin).1,2
Given these data, only supportive treatment, if any, remains to be considered in infants with bronchiolitis. Such treatments include maintenance of adequate hydration and oxygenation. Thus, most infants are only admitted to hospital because no reliable tool exists to predict who will have apnoea or respiratory failure. Clinical experience suggests a trial of continuous positive airway pressure in infants with respiratory failure, but again insufficient evidence exists from RCTs for this treatment.3 There remains an urgent need for large, well designed RCTs in this field.
For correspondence: Dr H Patel, McGill University Health Centre, Montreal, Quebec, Canada.
Source of funding: not stated.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.